利拉鲁肽(Liraglutide) - 药物靶点：GLP-1R_在研适应症：肥胖，超重，2型糖尿病_专利_临床

概要

基本信息

药物类型

重组多肽

别名

Liraglutide (Genetical Recombination)、Liraglutide Recombinant、Saxenda

+ [19]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Novo Nordisk A/SNovo Nordisk, Inc.

Nanexa AB

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2009-06-30),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

452

项与利拉鲁肽相关的临床试验

NCT06865365

/ Not yet recruiting临床4期IIT

Prospective, Randomized, Controlled Trial of Preoperative Use of Saxenda (Liraglutide) Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet. The investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.

开始日期2025-05-01

申办/合作机构

Medical University of Vienna

NCT06836284

/ Not yet recruitingN/AIIT

Evaluation of a Digital Treatment Tool in Combination with Anti-Obesity Medications

The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with anti-obesity medication in adolescents with obesity. The main question it aims to answer is:
- Can a combination of a digi-physical treatment tool and anti-obesity medication improve treatment outcomes for patients with obesity compared to patients treated with anti-obesity medications alone?
This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.

开始日期2025-04-01

申办/合作机构

Karolinska Institutet

[+1]

NCT06742710

/ Not yet recruiting临床4期IIT

Liraglutide Treatment in Obese Infertile PCOS Women

Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.
Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.

开始日期2025-02-10

申办/合作机构

北京大学第三医院（北京大学第三临床医学院）

100 项与利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽相关的专利（医药）

登录后查看更多信息

4,536

项与利拉鲁肽相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

2025-08-01·TISSUE & CELL

Liraglutide attenuates high glucose-induced endothelial cell senescence and dysfunction via SIRT1-mediated deacetylation of p53/p65

Article

作者: Wang, Yanru ; Zhong, Weili ; Yang, Ying

Endothelial aging is a critical pathogenic factor in various cardiovascular and metabolic disorders. Liraglutide (LIR), a glucagon-like peptide-1 receptor (GLP-1R) agonist used clinically to treat diabetes, controls blood sugar levels, and alleviates vascular stress, thereby protecting blood vessels. However, the mechanism by which it improves vascular aging remains to be elucidated. In this study, human umbilical vein endothelial cells were subjected to 30 mM glucose induction, followed by the addition of 1 μM LIR for 72 h. The findings indicated that LIR mitigated high glucose-induced endothelial cell senescence and downregulated the expression of markers linked to senescence, reactive oxygen species (ROS), and oxidative stress (p < 0.05). Additionally, it upregulated the expression of antioxidant markers and promoted angiogenesis and migration (p < 0.05). Western blot analysis of protein changes revealed that the therapeutic effects of LIR depend on SIRT1 and the acetylation of p53 and p65. Through SIRT1 overexpression and knockdown, we determined that SIRT1 regulates the acetylation of p53 and p65. Notably, the absence of SIRT1 diminished the therapeutic effects of LIR, whereas its overexpression enhanced these effects. Our findings suggest that high-glucose-induced endothelial cell aging and dysfunction may be involved in the pathogenesis of diabetic cardiovascular diseases (CVD). LIR treatment of high-glucose-induced vascular aging relies on the SIRT1-p53/p65 signaling axis. This study elucidates the mechanisms by which LIR ameliorates vascular aging and proposes a novel approach to mitigate vascular aging in elderly patients with diabetes.

2025-06-01·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Irisin and liraglutide combination therapy mitigates myocardial reperfusion injury in obese rats: Role of endoplasmic reticulum stress and apoptosis

Article

作者: Wang, Yibo ; Ma, Tao ; Li, Shiwen ; Sun, Guishun ; Wu, Bian ; Qu, Haiyan ; Wang, Junyu ; Li, Kunlin

BACKGROUND:

Obesity has become a global health concern, with its prevalence steadily rising across populations. Apart from its well-known association with various metabolic disorders, obesity has also been linked to an increased risk of cardiovascular diseases, including myocardial ischemia-reperfusion (IR) injury. This study aimed to assess how irisin and liraglutide, when used together, impact endoplasmic reticulum (ER) stress-induced apoptosis and PI3K/AKT signaling in obese rats after cardiac IR injury.

METHODS:

Thirty-six male Sprague-Dawley rats (200-230 g) were fed either a low-fat or high-fat diet for 12 weeks. The obese rats, which were fed a high-fat diet, underwent 30 min of left anterior descending coronary artery occlusion followed by 24 h of reperfusion. Prior to the IR procedure, the obese rats were treated with irisin (0.5 mg/kg/day) and/or liraglutide (0.07 mg/kg/day) for one week. Echocardiographic and hemodynamic parameters, LDH and CK-MB levels, the expression of proteins related to apoptosis (Bax, Bcl-2, cleaved caspase-3) and ER stress (CHOP, GRP78), as well as the phosphorylation of PI3K and AKT, were assessed.

RESULTS:

The combination therapy significantly improved cardiac function and reduced LDH and CK-MB levels (P<.05). Furthermore, this treatment downregulated proteins associated with ER stress, as well as pro-apoptotic markers Bax and cleaved caspase-3, while upregulating the anti-apoptotic protein Bcl-2. Additionally, it enhanced the phosphorylation of PI3K and AKT proteins (P<.05).

CONCLUSION:

Irisin/liraglutide combination therapy exerted cardioprotective effects against IR injury in obese rats, which were associated with the suppression of ER stress-mediated apoptosis, partly through the enhancement of PI3K/AKT signaling pathway activity.

942

项与利拉鲁肽相关的新闻（医药）

2025-04-22

·药事纵横

每周注射一次！甘李药业 GZR102 注射液获批临床

4月21日，甘李药业自主研发的GZR102注射液获得国家药监局的临床试验批准，作为一款基础胰岛素与胰高糖素样肽-1受体激动剂（GLP-1RA）的固定比例复方周制剂，GZR102的创新性在于将两种不同机制的降糖药物结合，并实现每周一次给药，这在当前糖尿病治疗领域具有显著的技术优势和临床价值。图源：CDE官网GZR102由甘李药业自主研发的超长效胰岛素GZR4和超长效GLP-1RA博凡格鲁肽（GZR18）以固定比例组成。其中，GZR4通过修饰人胰岛素分子形成“循环存储库”，皮下注射后可缓慢释放胰岛素，满足患者一周的基础胰岛素需求；而GZR18作为GLP-1RA，不仅能促进胰岛素分泌、抑制胰高血糖素释放，还能延缓胃排空、增加饱腹感，从而在降糖的同时实现体重控制。这种组合不仅符合国际临床指南推荐的基础胰岛素联合GLP-1RA治疗方案，还通过减少注射频率，从每日一次到每周一次，大幅提升患者依从性，这在糖尿病长期管理中至关重要。据统计，约50%的糖尿病患者因频繁注射而存在治疗依从性问题，导致血糖控制不佳。目前全球已上市的基础胰岛素/GLP-1RA复方制剂均为日制剂，例如诺和诺德的Xultophy（德谷胰岛素/利拉鲁肽）和赛诺菲的Soliqua（甘精胰岛素/利司那肽）。而GZR102作为首款进入临床阶段的周制剂复方药物，若能成功上市，将填补这一领域的技术空白，并为2型糖尿病患者提供更便捷的治疗选择。近年来，GLP-1类药物因显著的降糖和减重效果成为医药研发的热门赛道。根据统计，全球在研的GLP-1类药物已超过100款，其中诺和诺德的司美格鲁肽（Semaglutide）和礼来的替尔泊肽（Tirzepatide）占据主导地位。司美格鲁肽2023年全球销售额突破200亿美元，而替尔泊肽凭借双靶点（GLP-1/GIP）机制在减重效果上更具优势。甘李药业的GZR18作为对标司美格鲁肽的单靶点GLP-1RA，已在中国进入III期临床，并在美国开展针对肥胖适应症的II期试验，其减重疗效甚至计划与替尔泊肽进行头对头比较。GZR102的复方设计进一步拓展了GLP-1类药物的应用场景。一方面，基础胰岛素与GLP-1RA的联合可协同改善血糖控制，减少低血糖风险；另一方面，GZR18的减重特性能够抵消胰岛素治疗可能导致的体重增加副作用。根据甘李药业的早期临床试验数据，GZR102在降低糖化血红蛋白（HbA1c）和体重控制方面均优于单一组分。这种优势在糖尿病合并肥胖患者中尤为重要，我国成人糖尿病患病率达11.9%，其中超重或肥胖人群占比超过65%。从市场前景看，中国GLP-1类药物市场规模预计到2030年将超过600亿元，而复方制剂因其综合疗效可能占据更大份额。若GZR102能率先上市，甘李药业不仅能在国内市场打破外资垄断，还可依托其国际化布局（如GZR18的美国临床进展）参与全球竞争。尽管GZR102的前景光明，但其研发仍面临多重挑战。首先，复方制剂的药代动力学复杂性较高，需确保两种成分的释放速率和血药浓度曲线匹配。例如，GZR4的超长效特性依赖于与白蛋白的可逆结合，而GZR18作为两周给药一次的GLP-1RA，如何在复方中调整为周制剂并维持疗效，需要精细的剂型设计。其次，III期临床试验的规模和时长可能成为资金与时间的考验。截至2024年9月，GZR102项目的累计研发投入仅1507万元，而单方GZR4和GZR18的III期临床仍在进行中，复方制剂的后续开发成本或将大幅增加。此外，市场竞争的激烈程度不容小觑。除了外资企业的先发优势，国内药企如信达生物、恒瑞医药等也在加速布局GLP-1领域。例如，信达生物的玛仕度肽（IBI362）已进入III期临床，其双靶点设计（GLP-1/GCGR）在减重效果上表现突出。若这些竞品率先获批，可能挤压GZR102的市场空间。长期以来，国内药企在生物类似药和fast-follow药物上表现活跃，但在真正意义上的首创新药（First-in-Class）上成果有限。甘李药业通过GZR4和GZR18的自主研发，展示了在长效化技术上的积累，这为后续开发其他复方或新靶点药物奠定了基础。从更宏观的视角看，GZR102的成功可能推动糖尿病治疗模式的转变。当前，临床指南倾向于阶梯式治疗，如从口服药到胰岛素，而复方制剂有望通过更早的联合治疗实现血糖的快速稳定，减少并发症风险。此外，周制剂的便利性可能吸引更多潜在患者，如工作繁忙的年轻人群，接受规范治疗，从而改善整体疾病管理效率。不过，医药创新始终伴随高风险。GZR102从临床试验到最终上市仍需数年时间，且疗效与安全性需在更大样本中得到验证。投资者需关注甘李药业的研发管线推进效率及资金链稳定性，而患者则期待这一创新疗法能真正兑现“减少注射痛苦，提升生活质量”的承诺。信息来源：CDE官网、中国糖尿病防治指南（2024版）药事纵横投稿须知：稿费已上调，欢迎投稿

临床3期临床2期临床成功

2025-04-20

·赛柏蓝

「减肥药」封神时代，这些中国药企赚到大钱

编者按：本文来自医药投资部落，作者蓑笠独钓翁；赛柏蓝授权转载，编辑yuki“得GLP-1者得天下”，正成为当下全球医药产业的“铁律”。诺和诺德2024年财报显示，司美格鲁肽全系产品2024年全年合计收入2018.49亿丹麦克朗（约合292.96亿美元），仅略低于K药的294.82亿美元。考虑到司美格鲁肽正高速增长，而K药已步入“衰老期”，2025年司美格鲁肽拿下“全球药王”宝座，应该是大概率事件。凭借旗下以替尔泊肽为代表的多款GLP-1类药物的优异表现，礼来稳居全球药企市值排行榜的头把交椅，且断崖式领先其他同行。对于中国药企而言，在这场GLP-1类药物的研发竞争中，整体还是处于跟随者的角色，暂时还没有哪家药企在GLP-1制剂领域实质性地抓住红利。但是，在GLP-1原料药领域，已经有中国药企开始“狠狠赚钱”。近日，A股上市药企翰宇药业发布2025年一季报：单季度收入预计达2.9亿元至3.1亿元，同比增长93.00%至106.31%；预计实现归属于上市公司股东的净利润6000万元至7200万元，同比扭亏为盈。作为国内最早一批布局GLP-1原料药及制剂的药企，翰宇药业拥有固相合成、液相合成及生物酶催化等核心技术，能够高效合成GLP-1类似物（如利拉鲁肽、司美格鲁肽等），且纯度与收率行业领先。在产能方面，翰宇药业2022年投产的武汉基地，配备连续流合成、生物酶催化等先进工艺，GLP-1类原料药设计年产能达2-3吨；未来计划新增2条多肽原料药生产线，2025年总产能预计提升至5-8吨/年，重点满足司美格鲁肽仿制药原料药需求。自2023年以来，翰宇药业已累计签订多笔GLP-1相关海外订单，并已在2024年四季度集中进入履约发货期。对于困扰整个行业的关税问题，4月8日晚间，翰宇药业在投资者互动平台回复投资者称，根据美国“对等关税”豁免清单，其药品被列入关税豁免清单中，因此将不会受到美国“对等关税”影响。翰宇药业不是唯一在GLP-1原料药领域大有斩获的中国药企。3月底，A股上市公司诺泰生物发布业绩预告，预计2025年第一季度实现归母净利润为1.3亿元到1.7亿元，与上年同期相比增加96%~156%。2024年全年，诺泰生物实现营业收入16.25亿元，同比增长57.19%；归属净利润4.01亿元，同比增长145.94%。诺泰生物披露，业绩大幅增长的主要原因，是其发挥学科交叉及国际化BD团队的竞争优势，持续扩大优质客户规模，多肽原料药等销售收入实现较大增长。诺泰生物是又一家在全球GLP-1原料药供应链中，成功抢占一席之地的中国药企。目前，诺泰生物的GLP-1原料药，已经成功销往美国、欧洲、印度、加拿大等国家和地区，海外市场的收入占比已经超过50%。除了翰宇药业和诺泰生物以外，A股涉及GLP-1原料药的企业，还有圣诺生物和奥锐特，这两家企业的2025年一季报业绩也非常不错。GLP-1类药物无疑是当前代谢疾病领域的“黄金赛道”，对中国企业而言，抓住原料药优势，迅速攫取“第一桶金”，只是一个开端。接下来，有望站到舞台最中央的，或许是那些深度布局GLP-1制剂领域的中国药企们。END内容沟通：郑瑶（13810174402）

财报生物类似药

2025-04-19

·医药投资部落

减重药物的封神时代，这些中国药企赚到大钱

“得GLP-1者得天下”，正成为当下全球医药产业的铁律。诺和诺德2024年财报显示，司美格鲁肽全系产品2024年全年合计收入2018.49亿丹麦克朗（约合292.96亿美元），以非常微弱的劣势惜败于K药。但是，考虑到司美格鲁肽正处于高速增长期，而K药已经步入了“衰老期”，2025年司美格鲁肽拿下“全球药王”宝座，应该是大概率事件。凭借旗下以替尔泊肽为代表的多款GLP-1类药物的优异表现，礼来稳居全球药企市值排行榜的头把交椅，且断崖式领先其他同行。对于中国药企而言，在这场GLP-1类药物的研发竞争中，整体还是处于跟随者的角色，暂时还没有哪家药企在GLP-1制剂领域实质性地抓住历史的红利。但是，在GLP-1原料药领域，已经开始有中国药企，开始狠狠赚钱。近日，A股上市药企翰宇药业发布2025年一季报：公司单季度收入预计达2.9亿元至3.1亿元，同比增长93.00%至106.31%；预计实现归属于上市公司股东的净利润6000万元至7200万元，同比扭亏为盈。作为国内最早一批布局GLP-1原料药及制剂的药企，翰宇药业拥有固相合成、液相合成及生物酶催化等核心技术，能够高效合成GLP-1类似物（如利拉鲁肽、司美格鲁肽等），且纯度与收率行业领先。在产能方面，翰宇药业2022年投产的武汉基地，配备连续流合成、生物酶催化等先进工艺，GLP-1类原料药设计年产能达2-3吨；未来计划新增2条多肽原料药生产线，2025年总产能预计提升至5-8吨/年，重点满足司美格鲁肽仿制药原料药需求。自2023年以来，翰宇药业已累计签订多笔GLP-1相关海外订单，并已在2024年四季度集中进入履约发货期。对于困扰整个行业的关税问题，4月8日晚间，翰宇药业在投资者互动平台回复投资者称，根据美国“对等关税”豁免清单，公司药品被列入关税豁免清单中，因此将不会受到美国“对等关税”影响。翰宇药业不是唯一在GLP-1原料药领域大有斩获的中国药企。2025年3月底，A股上市公司诺泰生物发布业绩预告，预计2025年第一季度实现归属于母公司所有者的净利润为1.3亿元到1.7亿元，与上年同期相比增加96%~156%。2024年全年，诺泰生物实现营业收入16.25亿元，同比增长57.19%；归属净利润4.01亿元，同比增长145.94%。诺泰生物披露，业绩大幅增长的主要原因，是公司以“时间领先、技术领先”的经营理念，发挥学科交叉及国际化BD 团队的竞争优势，持续扩大优质客户规模，多肽原料药等销售收入实现较大增长。诺泰生物是又一家在全球GLP-1原料药供应链中，成功抢占一席之地的中国药企。目前，诺泰生物的GLP-1原料药，已经成功销往美国、欧洲、印度、加拿大等国家和地区，海外市场的收入占比已经超过50%。除了翰宇药业和诺泰生物以外，A股涉及GLP-1原料药的企业，还有圣诺生物和奥锐特，这两家企业的2025年一季报业绩也非常不错。GLP-1类药物无疑是当前代谢疾病领域的“黄金赛道”，对中国企业而言，抓住原料药优势，迅速攫取“第一桶金”，只是一个开端。接下来，有望站到舞台最中央的，或许是那些深度布局GLP-1制剂领域的中国药企们。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

财报

100 项与利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利拉鲁肽	A10BJ02	DB06655

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Novo Nordisk, Inc.	2014-12-23
超重	美国	Novo Nordisk, Inc.	2014-12-23
2型糖尿病	欧盟	Novo Nordisk A/S	2009-06-30
2型糖尿病	冰岛	Novo Nordisk A/S	2009-06-30
2型糖尿病	列支敦士登	Novo Nordisk A/S	2009-06-30
2型糖尿病	挪威	Novo Nordisk A/S	2009-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多囊卵巢综合征	临床3期	美国	Novo Nordisk A/S	2018-09-26
暴食症	临床3期	美国	Novo Nordisk A/S	2017-09-29
普拉德-威利综合症	临床3期	美国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	澳大利亚	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	加拿大	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	法国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	意大利	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	荷兰	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	新西兰	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	土耳其	Novo Nordisk A/S	2015-11-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02516657 (CTgov)	临床3期	1型糖尿病	5	liraglutide	淵淵衊夢壓窪糧衊淵艱(網積簾鏇鏇鏇鹹憲願糧) = 範餘艱艱顧襯網製製夢構蓋夢選築網鹽衊鏇廠 (構繭積淵糧遞衊網夢願, 35) 更多	-	2025-04-20
NCT04881110 (STARDUST, CTgov)	临床4期	2型糖尿病 \| 外周动脉疾病	60	liraglutide (Liraglutide Group)	築構鹹蓋鬱糧觸顧鹹獵(壓築糧衊夢選鏇夢願憲) = 壓鹹選製獵夢簾餘簾襯衊獵襯衊蓋鏇獵糧積廠 (醖網願顧鹹衊鹹鑰鬱襯, 5.9) 更多	-	2025-03-03
				Control (Control Group)	築構鹹蓋鬱糧觸顧鹹獵(壓築糧衊夢選鏇夢願憲) = 醖製網淵製淵願艱襯鹹衊獵襯衊蓋鏇獵糧積廠 (醖網願顧鹹衊鹹鑰鬱襯, 4.8) 更多
Pubmed 人工标引	N/A	超重 \| 肥胖	15,491	Tirzepatide 15 mg once weekly	餘築憲襯製壓願窪艱構(觸鬱選鹽夢鹽艱窪窪艱) = 築餘積願齋壓獵鏇膚鬱構簾襯遞築窪衊蓋選繭 (鹹憲齋構獵遞鏇積鏇糧 )	积极	2025-01-07
				Semaglutide 2.4 mg once weekly	餘築憲襯製壓願窪艱構(觸鬱選鹽夢鹽艱窪窪艱) = 艱蓋淵願醖顧鹹鑰鹽蓋構簾襯遞築窪衊蓋選繭 (鹹憲齋構獵遞鏇積鏇糧 )
NCT02098395 \| NCT01836523 (ADJUNCT ONE and ADJUNCT TWO, Pubmed \| J Diabetes Sci Technol)	临床3期	1型糖尿病 C-peptide	-	Liraglutide 1.8 mg	艱構選鑰蓋鑰窪鹽鬱廠(構鬱蓋構廠鏇齋膚願壓) = 鬱齋觸夢餘廠範鑰鹽顧遞積夢獵廠糧鹽齋壓顧 (齋憲築鑰壓齋齋醖衊鑰 ) 更多	-	2024-12-24
				Liraglutide 1.2 mg	艱構選鑰蓋鑰窪鹽鬱廠(構鬱蓋構廠鏇齋膚願壓) = 窪襯選築淵繭艱鬱膚窪遞積夢獵廠糧鹽齋壓顧 (齋憲築鑰壓齋齋醖衊鑰 ) 更多
NCT04883346 (LBODP002, CTgov)	临床2期	肥胖	34	liraglutide	積簾醖遞齋積願顧顧獵 = 憲鏇繭簾鬱廠鑰醖獵醖廠襯廠選範築鬱襯繭範 (鏇壓簾艱醖齋憲鹹範艱, 餘簾艱範鏇鹽餘簾窪網 ~ 醖壓獵獵衊範顧積獵襯) 更多	-	2024-11-20
Pubmed 人工标引	N/A	酒精使用障碍	227,866	Semaglutide	膚鏇夢齋餘遞構糧觸築(遞壓繭衊顧餘壓餘觸鏇) = A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92) of AUD hospitalization. 醖鬱壓廠蓋衊範簾鏇窪 (製獵觸顧願餘獵壓觸鹽 ) 更多	积极	2024-11-13
				Liraglutide
NCT04199728 (CTgov)	临床1/2期	阿片相关性障碍	27	Liraglutide Pen Injector (Investigational Group)	鬱繭憲鏇繭蓋憲蓋積醖(蓋膚壓憲鏇壓艱鏇夢鹹) = 鏇網簾鹹餘製糧願選壓製襯繭艱鏇醖觸築構襯 (膚範壓鑰築繭製鹽壓繭, NA) 更多	-	2024-11-06
				Placebo (Control Group)	鬱繭憲鏇繭蓋憲蓋積醖(蓋膚壓憲鏇壓艱鏇夢鹹) = 鏇構觸鹹淵願襯齋齋鑰製襯繭艱鏇醖觸築構襯 (膚範壓鑰築繭製鹽壓繭, 19.58) 更多
Drugs 人工标引	N/A	糖尿病 \| 肥胖	-	Ozempic (obesity)	獵構餘衊簾醖廠積選顧(簾積選鹽鏇觸獵鏇淵壓) = 鹽餘廠膚鏇鑰顧糧鑰衊廠醖夢憲襯憲廠蓋夢願 (願襯鏇窪膚窪衊網壓憲 )	积极	2024-09-13
				Saxenda (obesity)	獵構餘衊簾醖廠積選顧(簾積選鹽鏇觸獵鏇淵壓) = 積糧糧鏇夢糧築壓築醖廠醖夢憲襯憲廠蓋夢願 (願襯鏇窪膚窪衊網壓憲 )
NCT04775082 (SCALE Kids, Pubmed \| N Engl J Med) 人工标引	临床3期	肥胖	82	Liraglutide	壓製夢構繭鑰襯鬱選築(選餘網繭艱獵鏇襯網淵) = 製齋窪窪憲餘淵遞積鏇積糧築餘窪遞願鹹鑰膚 (願衊夢獵範觸衊構築齋 ) 更多	积极	2024-09-10
				Placebo	壓製夢構繭鑰襯鬱選築(選餘網繭艱獵鏇襯網淵) = 衊鑰觸糧鹽觸顧壓淵憲積糧築餘窪遞願鹹鑰膚 (願衊夢獵範觸衊構築齋 ) 更多
NEWS 人工标引	临床2期	阿尔茨海默症	204	Liraglutide	壓鏇遞鏇網膚鏇糧夢醖(鹹範鹽鹽膚鹽網遞衊網) = The trial’s primary endpoint was change in the cerebral glucose metabolic rate in the cortical regions of the brain, which was not met. 構積製鬱襯鹽襯製夢選 (淵糧艱窪壓鏇製製餘遞 ) 未达到更多	积极	2024-07-30
				Placebo